Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer

  • R. McLaughlin
  • D. O’Hanlon
  • T. McHale
  • C. E. Connolly
  • H. F. Given
Original Paper



The mortality and morbidity of patients with breast cancer can vary even between individuals with similar histological stage at diagnosis. Identification of those individuals with prognostically poorer tumours is an essential prerequisite in planning adjuvant therapies.

Some prognostic indices of tumour size, grade, oestrogen receptor status and nodal status are well established.


The aim of this study was to examine the prognostic role of information relating to proto-oncogene and tumour suppressor gene expression.


108 women with stage II breast cancer were studied. Tumour expression of p53 and bcl-2 were scored and then correlated with recurrence and mortality.


We have shown that individuals poorly expressing bcl-2 in their tumours have a poorer disease-free and overall survival than those who express bcl-2. When p53 was strongly expressed, it was associated with poorer disease-free and overall survival.


The profiling of individual tumour genetic expression of proto-oncogenes may allow for more specific identification of patients at higher risk’ of recurrence in breast cancer.


Breast Cancer Oestrogen Receptor Status Unilateral Breast Cancer Node Positive Tumour Tumour Suppressor Gene Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pezella F, Ralfkiaer E, Gatter KC, Mason DY. The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction.Br J Haematol 1990; 76: 58–64.CrossRefGoogle Scholar
  2. 2.
    Takechi M, Tanaka K, Hashimoto T, Asaoku H et al. Cytogenic, molecular biological and clinical study of B cell lymphomas with 14;18 translocation in Japanese patients.Leukemia 1991; 5: 1069–75.PubMedGoogle Scholar
  3. 3.
    Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 expression and long term survival in breast cancer.Am J Pathol 1994; 145: 1191–6.PubMedGoogle Scholar
  4. 4.
    Finalay CA, Hinds PVV, Levine AJ. The p53 proto-oncogene can act as a supressor of transformation.Cell 1989; 57: 1083–93.CrossRefGoogle Scholar
  5. 5.
    Lane DP, Benchimol S. p53 oncogene or anti-oncogene?Genes Dev 1990; 4: 1–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Varley JM, Brammer WJ, Lane DP et al. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.Oncogene 1991; 6: 413–21.PubMedGoogle Scholar
  7. 7.
    Cattorelli G, Rilke F, Andreola S et al. p53 expression in breast cancer.Int J Cancer 1988; 41: 178–83.CrossRefGoogle Scholar
  8. 8.
    Bartek J, Bartkova J, Vojtesek B et al. Patterns of expression of p53 tumour supressor in human breast tumours in situ and in vitro.Int J Cancer 1990; 46: 839–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Kinoshita T, Ueda M, Enomoto K et al. Comparison of p53 abnormalities in bilateral and unilateral breast cancer.Cancer 1995; 76; 12: 2504–09.CrossRefPubMedGoogle Scholar
  10. 10.
    UICC (1987) TNM classification of malignant tumours. International Union Against Cancer: Berlin.Google Scholar
  11. 11.
    Silvestrini R, Veneroni S, Daidone MG et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients.J Natl Cancer Inst 1994; 86: 499–504.CrossRefPubMedGoogle Scholar
  12. 12.
    Leoncini L, Del Veccio MT, Megha T et al. Correlations between apoptotic and proliferative indices in malignant nonHodgkins lymphomas.Am J Pathol 1993; 142: 755–63.PubMedGoogle Scholar
  13. 13.
    Iwaya K, Tsuda H, Hiraide H et al. Nuclear p53 immunoreaction associated with prognosis of breast cancer.Jpn J Cancer Res 1991; 82: 835–40.PubMedGoogle Scholar
  14. 14.
    Ostrowsky JL, Sawan A, Henry L et al. p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study.J Pathol 1991; 164: 75–81.CrossRefGoogle Scholar

Copyright information

© Springer 2001

Authors and Affiliations

  • R. McLaughlin
    • 2
  • D. O’Hanlon
    • 2
  • T. McHale
    • 1
    • 2
  • C. E. Connolly
    • 1
    • 2
  • H. F. Given
    • 2
  1. 1.Departments of PathologyUniversity College Hospital GalwayGalwayIreland
  2. 2.Departments of SurgeryUniversity College Hospital GalwayGalwayIreland

Personalised recommendations